Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OMER

Omeros Corporation

Oct 04 • 04:00PM ET

3.77

Dollar change -0.02
Percentage change -0.53	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWN SCHA VTWO IWO IWC SMLF SCHB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.35	Insider Own	4.46%	Shs Outstand	61.13M	Perf Week	-3.83%
Market Cap	218.47M	Forward P/E	-	EPS next Y	-2.24	Insider Trans	0.00%	Shs Float	55.36M	Perf Month	-4.80%
Income	-140.04M	PEG	-	EPS next Q	-0.77	Inst Own	43.27%	Short Float	21.39%	Perf Quarter	-3.08%
Sales	0.00M	P/S	-	EPS this Y	-59.93%	Inst Trans	-2.05%	Short Ratio	35.81	Perf Half Y	9.91%
Book/sh	-2.15	P/B	-	EPS next Y	25.61%	ROA	-45.24%	Short Interest	11.84M	Perf Year	44.44%
Cash/sh	2.74	P/C	1.37	EPS next 5Y	-	ROE	-576.33%	52W Range	0.92 - 5.68	Perf YTD	15.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.37%	ROI	-47.51%	52W High	-33.63%	Beta	1.48
Dividend TTM	-	Quick Ratio	3.41	Sales past 5Y	34.87%	Gross Margin	-	52W Low	309.78%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	3.41	EPS Y/Y TTM	-464.80%	Oper. Margin	0.00%	RSI (14)	44.48	Volatility	5.37% 5.79%
Employees	198	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.33	Target Price	43.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-62.97%	Payout	-	Rel Volume	0.74	Prev Close	3.79
Sales Surprise	-	EPS Surprise	14.73%	Sales Q/Q	-	Earnings	Aug 07 AMC	Avg Volume	330.66K	Price	3.77
SMA20	-1.93%	SMA50	-9.53%	SMA200	-2.21%	Trades		Volume	246,054	Change	-0.53%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-08-22	Downgrade	UBS	Buy → Neutral	$12 → $2
Nov-08-22	Downgrade	BofA Securities	Neutral → Underperform	$8 → $3
Jun-08-22	Downgrade	BofA Securities	Buy → Neutral	$12 → $4
Oct-08-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-21	Downgrade	Wedbush	Neutral → Underperform
Oct-01-21	Downgrade	Maxim Group	Buy → Hold
Sep-27-21	Initiated	JP Morgan	Neutral	$15
Feb-01-21	Initiated	UBS	Buy	$25
Oct-20-20	Initiated	BofA Securities	Buy	$21
Aug-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $32
Aug-14-20	Reiterated	Maxim Group	Buy	$25 → $20
May-06-19	Initiated	Cantor Fitzgerald	Overweight	$26
Jul-12-18	Initiated	Seaport Global Securities	Buy	$30
Mar-23-18	Downgrade	Wedbush	Outperform → Neutral	$47 → $19
Mar-05-18	Downgrade	Needham	Buy → Hold
Nov-08-17	Initiated	H.C. Wainwright	Buy	$30
May-11-17	Downgrade	Cantor Fitzgerald	Buy → Neutral	$21 → $15
Mar-17-17	Reiterated	Needham	Buy	$24 → $22
Mar-17-17	Reiterated	Maxim Group	Buy	$19 → $22
Nov-16-16	Reiterated	Wedbush	Outperform	$56 → $47

Show Previous Ratings

Aug-07-24 05:16PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance) -5.03% -5.78%
04:02PM	Omeros Corporation Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 (Business Wire) -10.68%
Jun-04-24 09:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -6.16%
Jun-03-24 09:00AM	Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 (Business Wire) +20.83%
01:10PM	Loading…
May-16-24 01:10PM	Q1 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -20.62%
03:10AM	Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ... (GuruFocus.com)
May-15-24 08:55PM	OMER Stock Earnings: Omeros Misses EPS for Q1 2024 (InvestorPlace)
04:11PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports First Quarter 2024 Financial Results (Business Wire)
May-10-24 08:50AM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 (Business Wire)
May-09-24 08:50AM	Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
Apr-02-24 12:41PM	Q4 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
11:22AM	Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-01-24 09:53PM	OMER Stock Earnings: Omeros Misses EPS for Q4 2023 (InvestorPlace) -7.54%
05:32PM	Loading…
05:32PM	Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results (GuruFocus.com)
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-27-24 08:30AM	Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 (Business Wire)
Mar-17-24 10:02AM	Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade (InvestorPlace)
Feb-20-24 09:00AM	Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (Business Wire)
Feb-07-24 09:34AM	3 Sleeper Stocks Under $15 Ready to Explode by 2029 (InvestorPlace)
Feb-01-24 09:11AM	Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-11-23 03:01PM	Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 09:43AM	Q3 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:33PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 08:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023 (Business Wire) +6.25%
Nov-03-23 09:05AM	Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (Business Wire)
09:05AM	Loading…
Nov-02-23 09:05AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire) +7.96%
Oct-19-23 08:30AM	Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer (Business Wire) -10.32%
Oct-16-23 08:36AM	Omeros stops kidney disease phase 3 after interim review fail, cutting thread holding up stock price (FierceBiotech.com) -32.16%
07:59AM	UPDATE 1-Omeros to terminate kidney disease trial as therapy fails late-stage study (Reuters)
07:44AM	Omeros to shut kidney disease trial as therapy fails in late-stage study (Reuters)
07:30AM	Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy (Business Wire)
Aug-09-23 08:08AM	Omeros: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Omeros Corporation Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-04-23 08:00AM	Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023 (Business Wire)
Jun-21-23 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -7.31%
Jun-12-23 02:47PM	Why Shares of Omeros Dropped on Monday (Motley Fool) -14.53%
08:45AM	Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress (Business Wire)
Jun-01-23 11:00AM	Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress (Business Wire) +17.42%
May-09-23 04:41PM	Omeros: Q1 Earnings Snapshot (AP Finance) +21.20%
04:02PM	Omeros Corporation Reports First Quarter 2023 Financial Results (Business Wire)
May-04-23 04:06PM	Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023 (Business Wire)
Apr-25-23 09:25AM	Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (Business Wire) -5.32%
Apr-10-23 08:45AM	Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program (Business Wire) +7.31%
Mar-29-23 09:07AM	Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day (Zacks) +9.42%
Mar-28-23 09:34AM	3 Medical Stocks Creating Wealth Despite Macro Challenges (Zacks)
Mar-14-23 11:11AM	Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript (Insider Monkey) +9.28%
10:06AM	Q4 2022 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-13-23 04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results (Business Wire) +5.83%
Mar-10-23 03:37PM	Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank (Business Wire) -10.93%
Mar-07-23 09:00AM	Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023 (Business Wire)
Feb-09-23 02:43PM	Why Omeros Stock Bolted Higher This Week (Motley Fool)
Feb-06-23 11:30AM	Why Omeros Corporation Stock Is Skyrocketing Today (Motley Fool) +61.17%
08:50AM	Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical (Business Wire)
Nov-09-22 04:02PM	Omeros Corporation Reports Third Quarter 2022 Financial Results (Business Wire) -11.88% -5.85%
Nov-08-22 08:30AM	Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab (Business Wire)
Nov-04-22 09:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022 (Business Wire) -5.03%
Nov-03-22 09:00AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire)
Oct-03-22 07:10AM	Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust (Business Wire) +10.79%
Sep-15-22 10:51AM	Omeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless (Benzinga) -25.97%
09:06AM	Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial (Business Wire)
09:02AM	I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19 (Business Wire)
Aug-17-22 08:40AM	Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab (Business Wire)
Aug-10-22 05:01PM	Omeros reports growing Omidria sales after deal with British eye care company (American City Business Journals) +20.32%
Aug-09-22 04:02PM	Omeros Corporation Reports Second Quarter 2022 Financial Results (Business Wire) -8.15%
Aug-08-22 11:35AM	How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own? (Simply Wall St.)
Aug-04-22 09:55AM	Wall Street Analysts See a 126% Upside in Omeros (OMER): Can the Stock Really Move This High? (Zacks) +6.51%
08:30AM	Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022 (Business Wire)
Jul-29-22 02:48PM	Why Omeros Corporation Stock Is Marching Higher Today (Motley Fool) +11.41%
08:45AM	FDA Grants Orphan Drug Designation to Omeros MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria (Business Wire)
Jul-05-22 05:46PM	Why Omeros Stock Is Freefalling Today (Motley Fool) -33.41% +15.86%
Jun-15-22 08:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +5.13%
May-10-22 04:02PM	Omeros Corporation Reports First Quarter 2022 Financial Results (Business Wire)
May-04-22 08:30AM	Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022 (Business Wire) +6.06%
Apr-20-22 08:45AM	Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA (Business Wire) -8.30%
Mar-01-22 04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results (Business Wire)
08:59AM	How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own? (Simply Wall St.)
Feb-28-22 08:34AM	Why Earnings Season Could Be Great for Omeros (OMER) (Zacks)
Feb-24-22 07:00AM	Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022 (Business Wire) +7.74%
Feb-03-22 09:38AM	Bellevue Asset Management, Llc Buys First Trust Low Duration Mortgage Opportunities ET, eBay ... (GuruFocus.com)
Jan-20-22 06:54AM	Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA (Benzinga)
Jan-19-22 05:52PM	Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA (Business Wire)
Dec-30-21 05:11PM	Omeros receives $126M in sale of drug franchise to British eye care company (American City Business Journals)
Dec-23-21 09:10AM	Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical (Business Wire)
Dec-20-21 09:30AM	OMER EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Omeros Corporation Investors with Losses to Inquire About Class Action Investigation - OMER (PR Newswire) +5.59%
Dec-15-21 11:34AM	Do Options Traders Know Something About Omeros (OMER) Stock We Don't? (Zacks)
Dec-03-21 08:17PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm (Newsfile) -6.15%
Dec-02-21 08:22PM	Seattle biotech Omeros selling drug franchise in deal valued at over $1B (American City Business Journals) +7.33%
07:30AM	Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion (Business Wire)
05:58AM	Omeros Shares Rally On Agreement to Sell Omidria Cataract Business (Investing.com)
Nov-30-21 07:42AM	Investors in Omeros (NASDAQ:OMER) have unfortunately lost 50% over the last three years (Simply Wall St.)
Nov-09-21 06:25PM	Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +10.76%
04:02PM	Omeros Corporation Reports Third Quarter 2021 Financial Results (Business Wire)
Nov-05-21 04:45PM	Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years (Benzinga)
08:40AM	Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial (Business Wire)
08:30AM	Omeros Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis (Business Wire)

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Demopulos Gregory A MD	Chairman, CEO & President	Nov 17 '23	Buy	1.68	15,000	25,200	123,945	Nov 21 08:11 PM
Demopulos Peter A MD	Director	Nov 15 '23	Buy	1.53	10,000	15,300	208,516	Nov 17 09:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OMER

Omeros Corporation

Upgrade your FINVIZ experience